(Q37498877)

20 August 2017

title

An antimicrobial stewardship program with a focus on reducing fluoroquinolone overuse (English)

1 reference

20 August 2017

Annie Wong-Beringer

1

1 reference

20 August 2017

Lee H Nguyen

2

1 reference

20 August 2017

Michelle Lee

3

1 reference

20 August 2017

Kimberly A Shriner

4

1 reference

20 August 2017

Jean Pallares

5

1 reference

20 August 2017

language of work or name

English

0 references

publication date

1 June 2009

1 reference

20 August 2017

1 reference

20 August 2017

volume

29

1 reference

20 August 2017

issue

6

1 reference

20 August 2017

page(s)

736-743

1 reference

Fluoroquinolone prescribing in the United States: 1995 to 2002.

20 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.6.736

A controlled trial of a critical pathway for treatment of community-acquired pneumonia. CAPITAL Study Investigators. Community-Acquired Pneumonia Intervention Trial Assessing Levofloxacin

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.6.736

Levofloxacin compared with imipenem/cilastatin followed by ciprofloxacin in adult patients with nosocomial pneumonia: A multicenter, prospective, randomized, open-label study

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.6.736

Antimicrobial drug prescribing for pneumonia in ambulatory care

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.6.736

Hospital-level rates of fluoroquinolone use and the risk of hospital-acquired infection with ciprofloxacin-nonsusceptible Pseudomonas aeruginosa

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.6.736

Relationship between fluoroquinolone use and changes in susceptibility to fluoroquinolones of selected pathogens in 10 United States teaching hospitals, 1991-2000.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.6.736

Blood culture and susceptibility results and allergy history do not influence fluoroquinolone use in the treatment of community-acquired pneumonia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.6.736

Fluoroquinolone utilization in the emergency departments of academic medical centers: prevalence of, and risk factors for, inappropriate use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.6.736

Antibiotic Therapy for Ambulatory Patients With Community-Acquired Pneumonia in an Emergency Department Setting

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.6.736

Levofloxacin failure in a patient with pneumococcal pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.6.736

Fluoroquinolone-resistant Streptococcus pneumoniae associated with levofloxacin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.6.736

Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.6.736

Levofloxacin treatment failure in a patient with fluoroquinolone-resistant Streptococcus pneumoniae pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.6.736

Failure of levofloxacin treatment in community-acquired pneumococcal pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.6.736

Fatal levofloxacin failure in treatment of a bacteremic patient infected with Streptococcus pneumoniae with a preexisting parC mutation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.6.736

Antibiotic resistance among gram-negative bacilli in US intensive care units: implications for fluoroquinolone use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.6.736

Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.6.736

Use of an efflux pump inhibitor to determine the prevalence of efflux pump-mediated fluoroquinolone resistance and multidrug resistance in Pseudomonas aeruginosa

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.6.736

Fluoroquinolone-resistant Pseudomonas aeruginosa: risk factors for acquisition and impact on outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.6.736

Reducing empirical use of fluoroquinolones for Pseudomonas aeruginosa infections improves outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.6.736

Antimicrobial resistance trends and outbreak frequency in United States hospitals

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.6.736

Longitudinal trends in antimicrobial susceptibilities across long-term-care facilities: emergence of fluoroquinolone resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.6.736

Fluoroquinolone use and Clostridium difficile-associated diarrhea.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.6.736

A large outbreak of Clostridium difficile-associated disease with an unexpected proportion of deaths and colectomies at a teaching hospital following increased fluoroquinolone use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.6.736

Clostridium difficile infections in a Canadian tertiary care hospital before and during a regional epidemic associated with the BI/NAP1/027 strain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.6.736

Hospital-wide restriction of clindamycin: effect on the incidence of Clostridium difficile-associated diarrhea and cost

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.6.736

Antibiotic utilization at the university hospital after introducing an antibiotic policy

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.6.736

The effect of formulary restriction in the use of antibiotics in an Italian hospital

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.6.736

Changes in the prevalence of vancomycin-resistant enterococci in response to antimicrobial formulary interventions: impact of progressive restrictions on use of vancomycin and third-generation cephalosporins

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.6.736

21 January 2018

Identifiers

DOI

10.1592/PHCO.29.6.736

1 reference

release_ul45wdcrerbhdjqrkbeozmvnia

20 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/ul45wdcrerbhdjqrkbeozmvnia

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference